Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms

Free Radical Biology and Medicine

Volumn 36, Issue 6, 2004, Pages 774-781

  Hung, Li Man ^a   Su, Ming Jai ^b   Chen, Jan Kan ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Arrhythmias; Blood pressure; BP; CK; Creatine kinase; ECG; Electrocardiogram; Free radicals; Heart rate; HR; I R; Ischemia reperfusion; Lactate dehydrogenase; LDH; LDL; Myocardial infarction; Nitric oxide synthase; Resveratrol

Indexed keywords

CREATINE KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; REDUCTION; REPERFUSION INJURY; UPREGULATION;

ANIMALIA;

EID: 1342306855     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2003.12.016     Document Type: Article

References (46)

1. Moncada S., Palmer R.M., Higger E.A. Nitric oxide: physiology, pathology, and pharmacology. Pharmacol. Rev. 43:1991;109-142.
2. Forstermann U., Closs E.I., Pollock J.S., Nakane M., Schwarz P., Gath I., Kleinert H. Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and function. Hypertension. 23:1994;1121-1131.
3. Mincada S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann. NY Acad. Sci. 811:1997;60-67.
4. McGowan F.X. Jr., Davis P.J., del Nido P.J., Sobek M., Allen J.W., Downing S.E. Endothelium-dependent regulation of coronary tone in the neonatal pig. Anesth. Analg. 79:1994;1094-1101.
5. Radomski M.W., Palmer R.M., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 92:1987;639-646.
6. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA. 88:1991;4651-4655.
7. Groves P.H., Lewis M.J., Cheadle H.A., Penny W.J. SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation. 87:1993;590-597.
8. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
9. Balligand J.L., Kelly R.A., Marsden P.A., Smith T.W., Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc. Natl. Acad. Sci. USA. 90:1993;347-351.
10. Park K.H., Rubin L.E., Gross S.S., Levi R. Nitric oxide is a mediator of hypoxic coronary vasodilatation, relation to adenosine and cyclooxygenase- derived metabolites. Circ. Res. 71:1992;992-1001.
11. Kitakaze M., Node K., Minamino T., Kosaka H., Shinozaki Y., Mori H., Inoue M., Hori M., Kamada T. Role of nitric oxide in regulation of coronary blood flow during myocardial ischemia in dogs. J. Am. Coll. Cardiol. 27:1996;1804-1812.
12. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br. J. Pharmacol. 105:1992;771-772.
13. Lefer A.M., Lefer D.J. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischemia-reperfusion. Cardiovasc. Res. 32:1996;743-751.
14. Williams M.W., Taft C.S., Ramnauth S., Zhao Z.Q., Vinten-Johansen J. Endogenous nitric oxide (NO) protects against ischemia-reperfusion injury in the rabbit. Cardiovasc. Res. 30:1995;79-86.
15. Hoshida S., Yamashita N., Igarashi J., Nishida M., Hori M., Kamada T., Kuzuya T., Tada M. Nitric oxide synthase protects the heart against ischemia-reperfusion injury in the rabbits. J. Pharmacol. Exp. Ther. 274:1995;413-418.
16. Constant J. Alcohol, ischemic heart disease, and the French paradox. Coron. Artery Dis. 8:1997;645-649.
17. Arichi H., Kimura Y., Okuda H., Bana K., Kozawa M., Arichi S. Effects of stilbene components of the roots of polygonum on lipid metabolism. Chem. Pharm. Bull. 30:1982;1766-1770.
18. Kimura Y., Okuda H., Arichi S. Effects of stilbene derivatives on arachidonate metabolism in leukocytes. Biochim. Biophys. Acta. 837:1985;209-212.
19. Ragazzi E., Froldi G., Fassina G. Resveratrol activity on guinea pig isolated trachea from normal and albumin-sensitized animals. Pharmacol. Res. Commun. 20:1988;79-82.
20. Bertelli A.A., Giovannini L., Giannessi D., Migliori M., Bernini W., Fregoni M., Bertelli A. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue React. 17:1995;1-3.
21. Jayatilake G.S., Jayasuriya H., Lee E.S., Koonchanok N.M., Geahlen R.L., Ashendel C.L., Mc Laughlin J.L., Chang C.J. Kinase inhibitors polygonum cuspidatum. J. Nat. Prod. 56:1993;1805-1810.
22. Rotondo S., Rajtar G., Manarinis S., Celardo A., Rotillio D., de Gaetano G., Evangelista V., Cerletti C. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Brit. J. Pharmacol. 123:1998;1691-1699.
23. Frankel E.N., Waterhouse A.L., Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet. 341:1993;1103-1104.
24. Hung L.M., Chen J.K., Huang S.S., Lee R.S., Su M.J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc. Res. 47:2000;549-555.
25. Hung L.M., Chen J.K., Lee R.S., Liang H.C., Su M.J. Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart. Free Radic. Biol. Med. 30:2001;877-883.
26. Hung L.M., Su M.J., Chu W.K., Chiao C.W., Chan W.F., Chen J.K. The protective effect of resveratrols on ischemia-reperfusion injuries of the rat hearts is correlated with antioxidant efficacy. Br. J. Pharmacol. 135:2002;1627-1633.
27. Walker M.J., Curtis M.J., Hearse D.J., Campbell R.W., Janse M.J., Yellon D.M., Cobbe S.M., Coker S.J., Harness J.B., Harron D.W. The Lambeth Convention: guidelines for the study of arrhythmias in ischemia, infarction and reperfusion. Cardiovasc. Res. 22:1988;447-455.
28. Nuedling S., Kahlert S., Loebbert K., Doevendans P.A., Meyer R., Vetter H., Grohe C. 17β-Estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc. Res. 43:1999;666-674.
29. Klein H.H., Puschmann S., Schaper J., Schaper W. The mechanism of the tetrazolium reaction in identifying experimental myocardial infarction. Arch. Pathol. Anat. 393:1981;287-297.
30. Furchgott R.F. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from retractor penis is organic nitrite and the endothelium-derived relaxing factor is nitric oxide. Vanhoutte P.M. Vasodilatation: vascular smooth muscle, peptides, autonomic nerves and endothelium. 1988;401-414 Raven Press, New York.
31. Warren J.B., Pons F., Brady A.J.B. Nitric oxide biology: implications for cardiovascular therapeutics. Cardiovasc. Res. 28:1994;25-30.
32. Szabolcs M.J., Ravalli S., Minanov O., Sciacca R.R., Michler R.E. Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection. Transplantation. 65:1998;804-812.
33. Rakhit R.D., Edwards R.J., Marber M.S. Nitric oxide, nitrates and ischaemic preconditioning. Cardiovasc. Res. 43:1999;621-627.
34. Schulz R., Nava E., Moncada S. Induction and potential biological relevance of a calcium-independent nitric oxide synthase in the myocardium. Br. J. Pharmacol. 105:1992;575-580.
35. Lipton S.A., Choi Y.B., Pan Z.H., Lei S.Z., Chen H.S., Sucher N.J., Loscalzo J., Singel D.J., Stamler J.S. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 364:1993;626-632.
36. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet. 343:1994;1199.
37. Elliott G.T. Monophosphoryl lipid A induces delayed preconditioning against cardiac ischemia-reperfusion injury. J. Mol. Cell Cardiol. 30:1998;3-17.
38. Mori E., Haramaki N., Ikeda H., Imaizumi T. Intra-coronary administration of L-arginine aggravates myocardial stunning through the production of peroxynitrite in dogs. Cardiovasc. Res. 40:1998;113-123.
39. Radi R., Beckman J.S., Bush K.M., Freeman B.A. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem. Biophys. 288:1991;481-487.
40. Baker C.S., Hall R.J., Evans T.J., Pomerance A., Maclouf J., Creminon C., Yacoub M.H., Polak J.M. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscle. Thromb. Vasc. Biol. 19:1999;646-655.
41. Jumrussirikul P., Dinerman J., Dawson T.M., Dawson V.L., Ekelund U., Georgakopoulos D., Schramm L.P., Calkins H., Snyder S.H., Hare J.M., Berger R.D. Interaction between neuronal nitric oxide synthase and inhibitory G protein activity in heart rate regulation in conscious mice. J. Clin. Invest. 102:1998;1279-1285.
42. Myers R.W., Pearlman A.S., Hyman R.M., Goldstein R.A., Kent K.M., Goldstein R.E., Epstein S.E. Beneficial effects of vagal stimulation and bradycardia during experimental acute myocardial ischemia. Circulation. 49:1974;943-947.
43. Pernow J., Wang Q.D. The role of the L-arginine/nitric oxide pathway in myocardial ischaemic and reperfusion injury. Acta Physiol. Scand. 167:1999;151-159.
44. Imamura G., Bertelli A.A., Otani H., Maulik N., Das D.K. Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am. J. Physiol. Heart Circ. Physiol. 282:2002;H1996-H2003.
45. Hattori R., Otani H., Maulik N., Das D.K. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 282:2002;H1988-H1995.
46. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Takeshita A. Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Circulation. 17:1999;690-692.